Core Viewpoint - Defence Therapeutics Inc. has announced an amendment to the terms of 800,000 Common Share purchase warrants, extending the expiry date by 12 months and reducing the exercise price to $0.75 per share [1]. Group 1: Warrant Amendments - The company is extending the expiry date of 775,000 warrants from October 30, 2026, to October 30, 2027, and for 25,000 warrants from November 29, 2026, to November 29, 2027 [1]. - The original exercise price of $1.00 has been reduced to $0.75 for both sets of warrants [1]. - None of the warrants have been exercised as of the announcement date [1]. Group 2: Company Overview - Defence Therapeutics is a publicly traded biotechnology company focused on improving cancer treatment efficacy and safety [2]. - The company utilizes its Accum® precision drug delivery platform to enhance the potency of antibody-drug conjugates (ADCs) and other complex biologics at lower doses [2]. - The goal of the company is to reduce side effects and improve access to advanced therapies through cutting-edge science and collaborations with pharmaceutical and biotech partners [2].

Core Viewpoint - Defence Therapeutics Inc. has successfully closed a private placement, raising approximately $9.6 million through the issuance of 17,445,455 units at a price of $0.55 per unit, which includes common shares and warrants [1][2]. Group 1: Private Placement Details - The private placement consists of 17,445,455 units, generating gross proceeds of $9,595,000.25 for the company [1]. - The company executed a binding term sheet with institutional investors for an additional $6 million as part of the private placement [2]. - Each unit includes one common share and one warrant, with warrants exercisable at $0.65 per share for 24 months [1][3]. Group 2: Use of Proceeds - The proceeds from the private placement will be utilized to advance the company's Antibody Drug Conjugate (ADC) and Radiopharmaceutical programs, develop partnerships, and for working capital [4]. Group 3: Warrant and Investor Details - A total of 10,909,091 warrants were issued, with an exercise price of $0.65 per share and a provision limiting ownership to 9.99% of outstanding shares [3]. - Investors received a corporate finance fee of 654,546 units and a non-refundable deposit of 118,182 units at the private placement price [3]. Group 4: Regulatory Compliance - All securities issued under this private placement are subject to resale restrictions in accordance with Canadian securities laws [5].

Core Viewpoint - Defence Therapeutics Inc. is launching a private placement to raise up to $11,000,000 through the issuance of 20,000,000 units at a price of $0.55 per unit, each consisting of one common share and one warrant [1] Group 1: Private Placement Details - The private placement aims to raise aggregate gross proceeds of $6,000,000 (CAD) from two institutional investors, with proceeds deposited in escrow prior to closing [2] - Upon closing, the units will be released from escrow, and the investors' proceeds will be provided to the company in monthly cash tranches of $333,333 (CAD) over an 18-month period [2][3] - The company will release shares in equal monthly installments of approximately 606,060 shares over the 18-month term, contingent upon cash payments [3] Group 2: Warrant and Fee Structure - A total of 10,909,091 warrants will be issued, exercisable at $0.65 (CAD) per share for 24 months, with an equity blocker provision limiting ownership to 9.99% of outstanding shares [4] - Investors will receive a corporate finance fee of $360,000 (CAD), payable in cash or through the issuance of 654,546 units at the private placement price [5] Group 3: Use of Proceeds - The proceeds from the private placement will be utilized to advance the company's Antibody Drug Conjugate (ADC) and Radiopharmaceutical programs, develop partnerships, and for working capital [6] Group 4: Regulatory and Compliance Information - All securities issued under the private placement will be subject to resale restrictions in accordance with Canadian securities laws, with the closing expected around March 6, 2026, pending CSE approval [7]